Depo-Provera Brain Tumor Lawsuits in Indiana

Studies show that long-term use of Depo-Provera significantly increases the risk of meningioma — a tumor in the tissue surrounding the brain. The risk ranges from 1.5x to 5.6x depending on duration of use and the study population. Meningiomas express progesterone receptors at 60–80% rates, and the synthetic progestin in Depo-Provera (MPA) stimulates tumor growth by binding to these receptors.

No. Approximately 80% of meningiomas are WHO Grade I (benign). However, "benign" is misleading — even Grade I meningiomas can cause severe symptoms (seizures, vision loss, cognitive decline) and require major brain surgery. WHO Grade II (atypical, 15–20%) and Grade III (malignant, 1–3%) are more aggressive. All grades are included in the lawsuit.

Most studies show elevated risk beginning after 1 year of use, with the risk increasing significantly after 3 years. However, there is no strict minimum. If you received Depo-Provera injections and were diagnosed with a meningioma, you should consult an attorney regardless of how long you used the drug.

Possibly. Because meningiomas are driven by progesterone receptor stimulation, removing the MPA stimulus by discontinuing Depo-Provera can slow growth or, in some cases, lead to tumor shrinkage. However, this is not guaranteed — many meningiomas continue to grow independently once established. Discontinuation should be combined with ongoing MRI monitoring.

Potentially yes. The statute of limitations in most states runs from when you knew or should have known about the connection between Depo-Provera and meningioma — not from the date of surgery. Since the FDA only added the meningioma warning in December 2025, many plaintiffs' discovery clocks may have started recently.

Meningiomas are slow-growing tumors that may take years to reach detectable size. A meningioma could be diagnosed months or even years after the last Depo-Provera injection. The key factor is cumulative MPA exposure over the total period of use, not when the last injection occurred.

Yes. You do not need to have had surgery to file a claim. A diagnosed meningioma being monitored with serial MRI imaging is still a compensable injury. You face ongoing medical costs, anxiety about tumor growth, and the possibility of future surgery. Many watchful-waiting patients eventually require intervention.

New or worsening headaches — particularly persistent headaches that are different from your normal pattern — warrant medical evaluation. While most headaches are not caused by brain tumors, the combination of Depo-Provera history plus new neurological symptoms justifies requesting brain imaging (MRI). Early detection significantly improves treatment outcomes.

Common symptoms include persistent headaches that worsen over time, vision changes (blurred or double vision, visual field loss), seizures, hearing problems, weakness or numbness, cognitive decline, and personality changes. Symptoms develop gradually because meningiomas are slow-growing tumors. If you used Depo-Provera and experience any of these symptoms, request brain imaging from your doctor.

Yes. Seizures occur in over one-third of meningioma patients. A seizure in someone with a history of Depo-Provera use should prompt immediate brain imaging. If you experience a seizure — especially a first-ever seizure — go to the emergency room. The ER will typically perform brain imaging that can detect a meningioma.

Plaintiffs allege that the science linking progestins to meningioma dates to the 1980s, and that Canada warned about the risk in 2015 — a decade before the U.S. label was updated. Pfizer has stated it became aware of the meningioma association in 2023 and submitted a label supplement to the FDA in February 2024. However, plaintiffs argue Pfizer had a duty to investigate known progestin-meningioma links much earlier.

Not necessarily. In June 2026, Pfizer reached an agreement in principle to resolve the meningioma cases consolidated in the federal MDL, but the terms are still being finalized and no compensation amounts have been made public. How the settlement will treat claims filed after it was announced is one of the details still being worked out. Two things remain true regardless. State statutes of limitations still set firm deadlines to file, and those windows vary by state and by when a woman connected her tumor to Depo-Provera. And the agreement does not cover cases pending in state courts. Because resolutions like this are usually built around claims already on file, women who believe they qualify are generally advised to have their eligibility reviewed promptly rather than wait. People's Justice does not file claims or give legal advice — we investigate the reported link and connect people who may qualify with attorneys who handle these cases. No outcome is guaranteed.

Yes. Even mild symptoms with a documented meningioma diagnosis are sufficient. Watchful-waiting cases (where the meningioma is monitored but not surgically removed) are compensable. You face ongoing medical monitoring costs, anxiety, quality-of-life impacts, and the risk that the tumor will grow and require future intervention.

No cases have settled or gone to trial yet. Based on comparable pharmaceutical brain injury litigation, projected values range from $75,000–$200,000 for monitored meningiomas, $200,000–$600,000 for surgical cases, and $600,000–$1,500,000+ for cases with permanent neurological damage. Actual values will depend on bellwether trial outcomes expected in 2026–2027.

Very high. The French BMJ study found a 5.6x increased risk for long-term users. The Frontiers review specifically recommended neurological monitoring for women with >10 years of use. With a decade of quarterly injections (40 injections totaling 6,000mg of MPA), your cumulative progestin exposure is enormous. Discuss screening with your doctor.

MDL 3140 is the multidistrict litigation that consolidates all federal Depo-Provera meningioma lawsuits in the Northern District of Florida under Judge M. Casey Rodgers. The MDL was established in February 2025. Consolidating cases allows for efficient pre-trial discovery and expert proceedings. Rule 702 hearings on general causation are scheduled for late May 2026.

Until December 2025, the U.S. Depo-Provera label did not mention meningioma. Your doctor likely had no information about this risk from the drug's official prescribing information. This is precisely the failure-to-warn that the lawsuit addresses — Pfizer's delay in updating the U.S. label left both patients and providers uninformed.

Generic versions contain the same active ingredient (medroxyprogesterone acetate / MPA) and carry the same meningioma risk. Named defendants include Pfizer as the brand manufacturer plus generic manufacturers including A-S Medication Solutions, Greenstone LLC, Prasco Laboratories, Pharmacia & Upjohn Company LLC, Preferred Pharmaceuticals Inc., and Viatris.

Potentially. If you suffered bone density loss alongside a meningioma, both injuries can be included in your claim. However, the bone density risk was disclosed via the 2004 black box warning, making the failure-to-warn argument stronger for meningioma (which had no U.S. warning until December 2025).

Yes. Data shows that 41.2% of Black women and 27.2% of Hispanic women reported using Depo-Provera between 2015–2019, compared to 24.5% of the general population. The drug was marketed as a convenient option for low-income communities, and many women report feeling pressured toward it over other contraceptive choices. This disparity means the brain tumor risk falls disproportionately on communities of color.

No. File as soon as possible. The statute of limitations is running regardless of the MDL timeline. Filing now ensures your case is in the pipeline when settlement programs are established. There is no advantage to waiting — and significant risk if you miss your filing deadline.

Discuss this with your healthcare provider. The updated FDA label (December 2025) recommends that providers monitor patients for meningioma symptoms and discontinue if a meningioma is diagnosed. If you have been using Depo-Provera for more than 2 years, the FDA already recommends switching to another contraceptive method due to bone density concerns. Do not stop any medication without consulting your doctor.

The Depo-Provera MDL is in early stages. Rule 702 hearings on general causation are scheduled for late May 2026. Bellwether trial selection will follow. The first trials may occur in late 2026 or 2027. Global settlement, if reached, could follow bellwether outcomes. From filing to resolution typically takes 2–5 years in pharmaceutical MDLs.

The 2004 black box warning is about bone mineral density loss (osteoporosis risk). The new December 2025 warning is specifically about meningioma brain tumors — a completely separate injury. Both are associated with long-term use, but they involve different mechanisms and different types of harm.

Most Depo-Provera attorneys work on contingency — typically 33–40% of the recovery. You owe no fee upfront and the attorney only gets paid if you receive compensation. In MDL cases, there may also be a common benefit fund (typically 4–8%) that compensates attorneys who performed work benefiting all plaintiffs.

Pfizer is one of the world's largest pharmaceutical companies with 2024 revenue exceeding $58 billion. While Depo-Provera is not Pfizer's largest product, the company's deep pockets mean it has the ability to pay substantial settlements. Pfizer's corporate conduct — prioritizing revenue over timely label updates — is central to punitive damages arguments.

Pfizer may try to argue it attempted to update the label in 2024 but was rejected by the FDA. However, this defense is weakened by several factors: Pfizer could have voluntarily added the warning through the CBE pathway without prior FDA approval, Canada warned in 2015 (9 years earlier), and the science linking progestins to meningioma dates to the 1980s. Pfizer's first label attempt in 2024 came only after the French BMJ study generated widespread media attention.

Generic manufacturers of MPA injectable contraceptive are also defendants in the MDL, including A-S Medication Solutions, Greenstone LLC (a Pfizer subsidiary), Prasco Laboratories, Pharmacia & Upjohn Company LLC, Preferred Pharmaceuticals Inc., and Viatris. If you used a generic version, you may have claims against the generic manufacturer.

Discuss this carefully with your doctor. Mirena releases levonorgestrel (a different progestin from MPA). The EMA review focused primarily on high-dose MPA. However, given the progesterone receptor mechanism of meningiomas, many neurologists recommend avoiding all progestational hormones after a meningioma diagnosis. The copper IUD (Paragard) is a hormone-free alternative.

The updated FDA label recommends discontinuing Depo-Provera immediately upon meningioma diagnosis. However, because Depo-Provera is a depot injection, the drug remains in your system for approximately 3 months after the last injection. You cannot "undo" a recent injection, but you should not receive any further injections. Discuss transition contraceptive options with your healthcare provider.

Stopping Depo-Provera does not cause withdrawal in the traditional sense, but you may experience changes: return of menstrual periods (which may be irregular for 6–18 months), mood changes, possible weight changes, and gradual bone density recovery. These transition effects are generally manageable and far outweigh the risk of continued progestin exposure with a diagnosed meningioma.

Potentially yes. If you received Depo-Provera during military service and were later diagnosed with a meningioma, you may establish service connection for VA disability benefits. You would need to demonstrate that the drug was prescribed during service and that the meningioma is connected to that treatment. A veteran service officer (VSO) or attorney specializing in VA claims can help navigate this process.

No. VA disability benefits and civil lawsuit settlements are separate. You can pursue both simultaneously. VA benefits are not reduced by civil lawsuit recoveries. However, if you receive a civil settlement, you should consult a financial advisor about how it may affect other means-tested government benefits.

Request your Service Treatment Records (STR) from the National Personnel Records Center (NPRC) using SF-180 form. If you receive VA healthcare, your VA medical file may also contain relevant records. Some records are available through the VA's Blue Button/MyHealtheVet online portal. Active duty members can access records through TRICARE and the Defense Health Agency.

If you have symptoms AND a history of Depo-Provera use, you can request a referral to a neurologist who can evaluate whether brain imaging is warranted. You can also reference the updated December 2025 FDA label, which instructs providers to "monitor patients on Depo-Provera CI for signs and symptoms of meningioma." If your doctor refuses, consider seeking a second opinion.

After initial meningioma detection, typical monitoring schedules include: MRI every 3–6 months for the first year, then every 6–12 months for years 2–5, then annually thereafter (for stable, non-surgical meningiomas). Surgical patients typically get an MRI 3 months post-surgery, then follow a similar surveillance schedule. Your neurosurgeon will customize the schedule based on tumor characteristics.

Insurance typically covers diagnostic MRI when ordered by a physician for symptoms. Screening MRI in asymptomatic patients may be harder to get covered. With the December 2025 FDA label update, physicians can now cite the official label recommendation to "monitor" for meningioma signs and symptoms as justification for imaging in symptomatic patients. Keep all bills — imaging costs are recoverable in your lawsuit.